GlassScriptPhysician profile
Leigh Ann Ruelo
NPI 1902969231
$8,471.58
in general payments reported to CMS, 2019-2025
33 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,246 · 2022: $1,992 · 2023: $2,549 · 2024: $1,678 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,149.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,580.69 | 2021-2025 | |
| Lilly USA, LLC | $815.86 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $814.98 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $733.20 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $644.86 | 2021-2025 | Opzelura |
| Amgen INC. | $582.27 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $494.48 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $399.09 | 2022-2025 | Sotyktu, Sprycel |
| Novartis Pharmaceuticals Corporation | $298.29 | 2022-2025 | |
| Janssen Biotech, INC. | $284.79 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $203.69 | 2022-2024 | Vtama |
| Pfizer INC. | $196.74 | 2021-2025 | |
| Leo Pharma INC. | $169.20 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $163.84 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $142.78 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $118.34 | 2021-2024 | Klisyri |
| Galderma Laboratories, L.P. | $95.93 | 2021-2025 | Nemluvio, Aklief |
| Janssen Scientific Affairs, LLC | $95.25 | 2022 | |
| Epi Health, LLC | $93.37 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $72.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Biofrontera INC. | $69.02 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.05 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $58.16 | 2024-2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $41.30 | 2022-2023 | Nuzyra |
| Nabriva Therapeutics, Plc | $40.10 | 2022 | |
| Krystal Biotech INC | $26.21 | 2023 | Vyjuvek |
| Mission Pharmacal Company | $25.81 | 2021 | |
| Arcutis Biotherapeutics, INC. | $20.73 | 2023 | |
| Botanix Sb INC | $17.31 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $15.25 | 2025 | Keytruda |
| Genentech USA, INC. | $13.54 | 2022 | |
| Organon LLC | $7.43 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Ruelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.